BluSense Diagnostics

medical devices

About

BluSense Diagnostics is a MedTech company founded in 2014 as a spin-off from the Technical University of Denmark. Based in Denmark with a presence in Taiwan, the company specializes in developing point-of-care blood testing devices aimed at detecting infectious diseases, including dengue, Zika, and COVID-19. The company utilizes expertise in microfluidics, biochemistry, electronics, optics, nanotechnology, computing, and product design to create innovative diagnostic solutions. Their products are designed to provide rapid, accurate, and user-friendly tests that facilitate timely disease detection, which is essential for effective management and control of infections. BluSense Diagnostics operates on a B2B model, serving healthcare providers, laboratories, and public health organizations. With a team of approximately 51-100 employees, BluSense Diagnostics has shown significant growth, reporting revenues around $18.9 million. The leadership team includes CEO Filippo Bosco, CSO Marco Donolato, and COO Robert Burger, who contribute strong scientific and operational expertise to the company.

Technologies

CloudFlare Hosting Nginx YouTube Mobile Friendly

Keywords

medical equipment manufacturing biotechnology optical detection dengue rapid test scalable biosensors point-of-care diagnostics medical equipment and supplies manufacturing public health surveillance infectious disease testing research and development rapid results nanotechnology automated systems portable testing user-friendly devices biomarker analysis lab-grade results molecular detection mosquito-borne viruses compact design scandinavian engineering reproducibility viral research outbreak response tools healthcare molecular methods resource-limited settings integrated diagnostic systems diagnostic platforms molecular studies

Location

3 Fruebjergvej, Copenhagen, Capital Region of Denmark, Denmark, 2100

Related Companies

Companies in the same industry